docetaxel anhydrous has been researched along with plx4032 in 4 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,657 | 103 | 1,587 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | plx4032 (IC50) |
|---|---|---|---|
| Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Cheng, Y; Tian, H; Wang, X; Xia, X; Zhang, W | 1 |
| Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 2 |
4 other study(ies) available for docetaxel anhydrous and plx4032
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer.
Topics: Animals; Benzoxazoles; Biological Availability; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Female; HT29 Cells; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Vemurafenib; Xenograft Model Antitumor Assays | 2019 |
Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cisplatin; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Mitoxantrone; Paclitaxel; Vemurafenib | 2023 |
Daphnetin, a Coumarin with Anticancer Potential against Human Melanoma: In Vitro Study of Its Effective Combination with Selected Cytostatic Drugs.
Topics: Cisplatin; Coumarins; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mitoxantrone; Vemurafenib | 2023 |